Literature DB >> 8722108

Pharmacokinetics and molecular detoxication.

J R Cashman1, B Y Perotti, C E Berkman, J Lin.   

Abstract

This paper presents a comprehensive overview of the pharmacokinetic parameters used from in vivo and in vitro studies that are important in order to understand the major conceptual approaches of toxicokinetics and the disposition of environmental chemicals. In vitro biochemical information concerning the detoxication of environmental chemicals is also presented. The discussion leads to a more complete appreciation for the use of in vitro measurements for in vivo correlations. The concept of interspecies scaling in the interpolation and extrapolation of fundamental biochemical metabolic processes is illustrated with a number of examples. Additional examples of in vitro-in vivo correlations are presented in the evaluation of the impact of chemical exposure to humans. Finally, several important metabolic detoxication enzymes are presented, including the mammalian microsomal cytochrome P450 and flavin-containing monooxygenases as well as carboxylesterases and glucuronosyltransferases, to provide insight into the processes of chemical detoxication in mammalian tissue and blood. Because interspecies scaling and the pharmacokinetics of chemical disposition have already shown their usefulness in understanding some examples of chemical disposition, our summary focuses on showing the usefulness of the pharmacokinetic equations and providing confidence in using the approach for in vitro-in vivo correlations. Ultimately, the presentation may provide the reader with a conceptual framework for future evaluation of the human health risks associated with environmental toxicants.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8722108      PMCID: PMC1469571          DOI: 10.1289/ehp.96104s123

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  116 in total

1.  A preliminary genetic interpretation of the esterase isozymes of human tissues.

Authors:  P M Coates; M A Mestriner; D A Hopkinson
Journal:  Ann Hum Genet       Date:  1975-07       Impact factor: 1.670

2.  Congenital familial nonhemolytic jaundice with kernicterus.

Authors:  J F CRIGLER; V A NAJJAR
Journal:  Pediatrics       Date:  1952-08       Impact factor: 7.124

3.  Activation of the O-glucuronide of the carcinogen N-hydroxy-N-2-fluorenylacetamide by enzymatic deacetylation in vitro: formation of fluorenylamine-tRNA adducts.

Authors:  R A Cardona; C M King
Journal:  Biochem Pharmacol       Date:  1976-05-01       Impact factor: 5.858

Review 4.  Structural and catalytic properties of the mammalian flavin-containing monooxygenase.

Authors:  J R Cashman
Journal:  Chem Res Toxicol       Date:  1995-03       Impact factor: 3.739

5.  Interspecies correlation of plasma concentration history of methotrexate (NSC-740).

Authors:  R Dedrick; K B Bischoff; D S Zaharko
Journal:  Cancer Chemother Rep       Date:  1970-04

6.  In vitro-in vivo correlations of human (S)-nicotine metabolism.

Authors:  C E Berkman; S B Park; S A Wrighton; J R Cashman
Journal:  Biochem Pharmacol       Date:  1995-08-08       Impact factor: 5.858

7.  Possible mechanism of liver necrosis caused by aromatic organic compounds.

Authors:  B B Brodie; W D Reid; A K Cho; G Sipes; G Krishna; J R Gillette
Journal:  Proc Natl Acad Sci U S A       Date:  1971-01       Impact factor: 11.205

8.  Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase.

Authors:  R C Sorenson; S L Primo-Parmo; C L Kuo; S Adkins; O Lockridge; B N La Du
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

View more
  18 in total

Review 1.  Carboxylesterase inhibitors.

Authors:  M Jason Hatfield; Philip M Potter
Journal:  Expert Opin Ther Pat       Date:  2011-05-24       Impact factor: 6.674

2.  Requirements for mammalian carboxylesterase inhibition by substituted ethane-1,2-diones.

Authors:  Elizabeth I Parkinson; M Jason Hatfield; Lyudmila Tsurkan; Janice L Hyatt; Carol C Edwards; Latorya D Hicks; Bing Yan; Philip M Potter
Journal:  Bioorg Med Chem       Date:  2011-07-04       Impact factor: 3.641

Review 3.  Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.

Authors:  Upendra A Argikar; Philip M Potter; J Matthew Hutzler; Punit H Marathe
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

Review 4.  Biochemical and molecular aspects of 1,2-dimethylhydrazine (DMH)-induced colon carcinogenesis: a review.

Authors:  Karthikkumar Venkatachalam; Ramachandran Vinayagam; Mariadoss Arokia Vijaya Anand; Nurulfiza Mat Isa; Rajasekar Ponnaiyan
Journal:  Toxicol Res (Camb)       Date:  2020-03-30       Impact factor: 3.524

5.  Facile synthesis of 1,2-dione-containing abietane analogues for the generation of human carboxylesterase inhibitors.

Authors:  Randall J Binder; M Jason Hatfield; Liying Chi; Philip M Potter
Journal:  Eur J Med Chem       Date:  2018-02-19       Impact factor: 6.514

6.  Genetic Polymorphisms of Pharmacogenes among the Genetically Isolated Circassian Subpopulation from Jordan.

Authors:  Laith N Al-Eitan; Doaa M Rababa'h; Nancy M Hakooz; Mansour A Alghamdi; Rana B Dajani
Journal:  J Pers Med       Date:  2020-01-06

Review 7.  Carboxylesterases: General detoxifying enzymes.

Authors:  M Jason Hatfield; Robyn A Umans; Janice L Hyatt; Carol C Edwards; Monika Wierdl; Lyudmila Tsurkan; Michael R Taylor; Philip M Potter
Journal:  Chem Biol Interact       Date:  2016-02-15       Impact factor: 5.192

8.  Potent, Irreversible Inhibition of Human Carboxylesterases by Tanshinone Anhydrides Isolated from Salvia miltiorrhiza ("Danshen").

Authors:  M Jason Hatfield; Randall J Binder; Rowan Gannon; Ellie M Fratt; John Bowling; Philip M Potter
Journal:  J Nat Prod       Date:  2018-10-23       Impact factor: 4.050

9.  Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity.

Authors:  Latorya D Hicks; Janice L Hyatt; Shana Stoddard; Lyudmila Tsurkan; Carol C Edwards; Randy M Wadkins; Philip M Potter
Journal:  J Med Chem       Date:  2009-06-25       Impact factor: 7.446

10.  Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils.

Authors:  Latorya D Hicks; Janice L Hyatt; Teri Moak; Carol C Edwards; Lyudmila Tsurkan; Monika Wierdl; Antonio M Ferreira; Randy M Wadkins; Philip M Potter
Journal:  Bioorg Med Chem       Date:  2007-03-12       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.